Literature DB >> 7486934

In vitro activities of PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite against Mycobacterium avium complex.

S C Meyer1, S K Majumder, M H Cynamon.   

Abstract

PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite were evaluated for in vitro activity against 31 clinical Mycobacterium avium complex isolates. Broth dilution MICs of PS-15 ranged from 16 to 64 micrograms/ml. The cyclic metabolite was three to five times more active than the parent compound. Further evaluation of these compounds in an M. avium-infected murine test system will be of interest.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7486934      PMCID： PMC162841          DOI： 10.1128/AAC.39.8.1862

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  4 in total

Review 1.  Prophylaxis for opportunistic infections in patients with HIV infection.

Authors:  J E Gallant; R D Moore; R E Chaisson
Journal:  Ann Intern Med       Date:  1994-06-01       Impact factor: 25.391

2.  Anti-Pneumocystis carinii activity of PS-15, a new biguanide folate antagonist.

Authors:  W T Hughes; D P Jacobus; C Canfield; J Killmar
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

3.  PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists.

Authors:  C J Canfield; W K Milhous; A L Ager; R N Rossan; T R Sweeney; N J Lewis; D P Jacobus
Journal:  Am J Trop Med Hyg       Date:  1993-07       Impact factor: 2.345

4.  Evaluation of WR250417 (a proguanil analog) for causal prophylactic activity in the Plasmodium cynomolgi-Macaca mulatta model.

Authors:  M D Edstein; K D Corcoran; G D Shanks; M Ngampochjana; P Hansukjariya; J Sattabongkot; H K Webster; K H Rieckmann
Journal:  Am J Trop Med Hyg       Date:  1994-02       Impact factor: 2.345
  4 in total
  9 in total

1.  Enhanced in vitro activity of dihydrofolate reductase and dihydropteroase synthase inhibitors in combination against Nocardia spp.

Authors:  Deborah M Thielking; Michelle S Destefano; Michael H Cynamon; Anthony E T Yeo
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 2.  Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.

Authors:  Yusuke Minato; Joshua M Thiede; Shannon Lynn Kordus; Edward J McKlveen; Breanna J Turman; Anthony D Baughn
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

3.  Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model.

Authors:  M Brun-Pascaud; P Rajagopalan-Levasseur; F Chau; G Bertrand; L Garry; F Derouin; P M Girard
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.

Authors:  M Brun-Pascaud; F Chau; L Garry; D Jacobus; F Derouin; P M Girard
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.

Authors:  A'Lissa B Gerum; Jonathan E Ulmer; David P Jacobus; Norman P Jensen; David R Sherman; Carol Hopkins Sibley
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil.

Authors:  D A Fidock; T E Wellems
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

7.  Enhanced in vitro activity of WR99210 in combination with dapsone against Mycobacterium avium complex.

Authors:  L M Shah; M S DeStefano; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  Identification of P218 as a potent inhibitor of Mycobacterium ulcerans DHFR.

Authors:  Gustavo P Riboldi; Rachael Zigweid; Peter J Myler; Stephen J Mayclin; Rafael M Couñago; Bart L Staker
Journal:  RSC Med Chem       Date:  2020-10-22

9.  Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase.

Authors:  W J Suling; L E Seitz; V Pathak; L Westbrook; E W Barrow; S Zywno-Van-Ginkel; R C Reynolds; J R Piper; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.